(Q36532142)

14 August 2017

1 reference

title

Quetiapine: efficacy, tolerability and safety in schizophrenia (English)

1 reference

14 August 2017

1 reference

Vladimir Lerner

2

1 reference

ORCID Public Data File 2021

author name string

Chanoch Miodownik

series ordinal

1

1 reference

14 August 2017

publication date

1 July 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

7

1 reference

14 August 2017

page(s)

983-992

1 reference

Clinical effectiveness in adults with chronic schizophrenia

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Review of quetiapine and its clinical applications in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine: a review of its safety in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine. A review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Clinical effectiveness in first-episode patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Dosing and switching strategies for quetiapine fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

The effect of quetiapine on aggression and hostility in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Managing acute exacerbations of schizophrenia: focus on quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Rapid dose escalation with quetiapine: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Death associated with quetiapine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Pediatric case report of quetiapine overdose and QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Effects of quetiapine on cognitive functions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine-related tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine-Induced extrapyramidal side effects in patients with Parkinson's disease: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Extrapyramidal symptoms associated with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Acute akathisia associated with quetiapine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine-induced myoclonus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Seizures associated with quetiapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Nizatidine for the treatment of patients with quetiapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Weight loss and anorexia with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine-associated hyperglycemia and hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Novel antipsychotics and severe hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

A study of quetiapine: efficacy and tolerability in psychotic adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

A 6-month prospective observational study on the effects of quetiapine on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

A new atypical antipsychotic: quetiapine-induced sexual dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Prolactin elevation with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Abnormal prolactin elevation in a schizophrenic patient in treatment with quetiapine and mirtazapine. The role of opioid system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Elevated prolactin levels in male youths treated with risperidone and quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

21 January 2018

Quetiapine and pregnancy

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Safety of quetiapine during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Clinical utilization of atypical antipsychotics in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Excretion of quetiapine in breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Myocarditis with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Agranulocytosis and granulocytopenia associated with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Acute neutropenia in a patient treated with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Is leukopenia associated with divalproex and/or quetiapine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine and leukopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Thrombotic thrombocytopenic purpura associated with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine treatment in early psychosis: no evidence of cataracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Twice-yearly exams unnecessary for patients taking quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Cataract occurrence with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine-associated and dose-related hypomania in a woman with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Manic symptoms associated with quetiapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine-associated depression in a patient with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Quetiapine poisoning: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Fatalities associated with therapeutic use and overdose of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Factors influencing relapse in the long-term course of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Intranasal quetiapine abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

Neuroendocrine effects of quetiapine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.983

21 January 2018

Identifiers

DOI

10.1586/14737175.6.7.983

1 reference

14 August 2017

1 reference